We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+28.05%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
AUM
$10.3B
AUM Growth
+$5.25B
Cap. Flow
+$4.62B
Cap. Flow %
45%
Top 10 Hldgs %
41.75%
Holding
2,600
New
918
Increased
493
Reduced
472
Closed
701

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$353M
2
MSFT icon
Microsoft
MSFT
+$352M
3
AAPL icon
Apple
AAPL
+$256M
4
BABA icon
Alibaba
BABA
+$189M
5
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$125M

Sector Composition

Rank Sector Weight
1 Technology 14.28%
2 Consumer Discretionary 10.77%
3 Healthcare 5.09%
4 Industrials 4.03%
5 Financials 3.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HPE icon
2126
Hewlett Packard
HPE
$70.8B
-154,311
Closed -$1.45M
HPQ icon
2127
HP
HPQ
$27.2B
-92,255
Closed -$1.75M
HRTX icon
2128
Heron Therapeutics
HRTX
$60.4M
-62,210
Closed -$922K
HUYA
2129
Huya Inc
HUYA
$498M
-30,116
Closed -$721K
HWC icon
2130
Hancock Whitney
HWC
$6.05B
-16,414
Closed -$309K
HYG icon
2131
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.8B
-200,000
Closed -$16.8M
HYLN icon
2132
Hyliion Holdings
HYLN
$595M
-3,436
Closed -$171K
IBB icon
2133
iShares Biotechnology ETF
IBB
$10.7B
-100,802
Closed -$13.7M
IBEX icon
2134
IBEX
IBEX
$490M
-96,651
Closed -$1.49M
IBM icon
2135
IBM
IBM
$222B
-9,225
Closed -$1.07M
IBOC icon
2136
International Bancshares
IBOC
$4.45B
-25,997
Closed -$677K
IBRX icon
2137
ImmunityBio
IBRX
$8.26B
-11,892
Closed -$82K
IDA icon
2138
Idacorp
IDA
$7.94B
-16,166
Closed -$1.29M
IGMS
2139
DELISTED
IGM Biosciences
IGMS
-4,295
Closed -$317K
BRSL
2140
Brightstar Lottery PLC
BRSL
$2.21B
-27,130
Closed -$302K
IIIV icon
2141
i3 Verticals
IIIV
$301M
-24,672
Closed -$623K
IJR icon
2142
PUT
iShares Core S&P Small-Cap ETF
IJR
$111B
-50,000
Closed -$3.51M
IMMR icon
2143
Immersion
IMMR
$249M
-12,780
Closed -$90K
IMO icon
2144
Imperial Oil
IMO
$66.8B
-35,963
Closed -$430K
IMXI icon
2145
International Money Express
IMXI
$427M
-31,237
Closed -$449K
INDB icon
2146
Independent Bank
INDB
$3.97B
-9,006
Closed -$472K
INFY icon
2147
Infosys
INFY
$48.4B
-10,397
Closed -$144K
INSG icon
2148
Inseego
INSG
$72.1M
-1,847
Closed -$191K
INTC icon
2149
Intel
INTC
$476B
-9,290
Closed -$481K
INVA icon
2150
Innoviva
INVA
$1.52B
-22,318
Closed -$233K

Similar funds

Michael Gelband's Q4 2020 Portfolio in Review

As of Q4 2020, Michael Gelband held 2,600 positions worth $10.3B, up 105% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Michael Gelband deployed $4.62B of net new capital in Q4 2020, opening 918 new positions and adding to 493 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Charles Schwab, an estimated $82M trimmed.

  • Michael Gelband's largest Q4 2020 buy was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
  • Michael Gelband added most to Amazon in Q4 2020, an estimated $353M increase.
  • Michael Gelband's biggest Q4 2020 reduction was Charles Schwab, cutting an estimated $82M.
  • Michael Gelband fully exited Eli Lilly in Q4 2020, selling an estimated $21.7M.
  • Michael Gelband's ten largest holdings make up 42% of its $10.3B portfolio in Q4 2020.
  • Michael Gelband opened 918 new positions and closed 701 in Q4 2020.
  • Michael Gelband's portfolio value rose 105% quarter-over-quarter to $10.3B.

Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.